Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial (rTMS)
Repeated Transcranial Magnetic Stimulation (rTMS) for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial
Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential underlying mechanisms by which rTMS alleviates clinical symptoms in IBS-D patients.
Design: This is a clinical trial that uses clinical symptom scales to assess the therapeutic effect of rTMS on IBS-D patients. Meanwhile, gut microbiota and metabolite profiling, as well as the methane-hydrogen breath test, will be applied to investigate the mechanism of action from the perspectives of gut microecology, intestinal motility, and metabolism, so as to provide scientific evidence for the clinical application of rTMS in the treatment of IBS-D.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Background: A large number of studies have demonstrated that repetitive transcranial magnetic stimulation (rTMS) can alleviate chronic pain. Its potential mechanisms include modulating cortical excitability, improving cerebral blood flow and metabolism, regulating neurotransmitters and gene expression, and inducing neuroplasticity. Previous findings indicate that the gut-brain neural circuit involving the insular cortex and anterior cingulate cortex serves as a key pathway regulating chronic visceral pain in irritable bowel syndrome (IBS). Studies have also shown that transcranial magnetic stimulation (TMS) can reduce visceral hypersensitivity in patients with IBS. On this basis, the present study further investigates whether rTMS can improve diarrheal symptoms in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), in order to provide a more reliable and effective therapeutic strategy for clinical practice.
Objectives:
This study aims to evaluate the overall clinical efficacy of rTMS in the treatment of IBS-D, including diarrhea, abdominal pain, quality of life, psychiatric symptoms (anxiety and depression), and sleep disturbance. Meanwhile, the underlying mechanisms of rTMS will be explored using gut microbiota and metabolomic profiling, as well as the methane-hydrogen breath test.
Methods:
This is a clinical trial designed to evaluate the efficacy of rTMS in treating chronic diarrhea in IBS-D patients. A total of 46 IBS-D patients meeting eligibility criteria will be randomly assigned to receive either real rTMS (n=23) or sham rTMS (n=23).
The treatment will last for 3 weeks. The real rTMS group will receive 1 Hz stimulation, 20 minutes per session. The sham rTMS group will receive 0 Hz stimulation (sham condition), 20 minutes per session.
Low-frequency rTMS (1 Hz) will be applied over the medial prefrontal cortex (mPFC) using a magnetic stimulator manufactured by Wuhan IRide Company. Stimulation intensity will be set at 80% of the resting motor threshold (RMT). RMT is defined as the minimal stimulus intensity required to evoke a motor evoked potential (MEP) amplitude of ≥50 μV in at least 5 out of 10 consecutive trials.
The coil will be placed tangentially over the mPFC. Patients will remain seated quietly with minimal head movement during the entire session.For the real rTMS group: 1 Hz frequency, 80% RMT intensity, 1100 pulses per session, with each pulse train lasting 2 seconds, and a total session duration of 20 minutes.For the sham rTMS group: the coil is positioned identically but without effective magnetic stimulation, while pre-recorded sound is played to mimic the acoustic feedback of real rTMS.
Outcome Assessments:
Clinical assessments will include diarrhea, abdominal pain, quality of life, intestinal sensitivity, mood status, and sleep.
Mechanistic evaluations will be performed using gut microbiota and metabolite analysis, combined with methane-hydrogen breath test, to explore the mechanisms underlying rTMS effects on chronic diarrhea in IBS-D patients.
Gut microbiota data will be analyzed to compare differences between the treatment and control groups before and after intervention. Correlation analyses will be conducted between clinical improvement and changes in microbial and metabolic profiles.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Xiuji Kan
- Puhelinnumero: 15339525666
- Sähköposti: xiujikan@163.com
Opiskelupaikat
-
-
Jiangsu
-
Suzhou, Jiangsu, Kiina, 215006
- Rekrytointi
- The First Affiliated Hospital of Soochow University
-
Ottaa yhteyttä:
- Wu Shuangjie
- Puhelinnumero: +8651267972743
- Sähköposti: sdfyec@163.com
-
Päätutkija:
- Xiuji Kan
-
Päätutkija:
- Ruixia Weng, Dr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
Eligible participants had to be between 18- 60 years of age and fulfill the Rome IV criteria for IBS-D. Specifically, patients must have experienced recurrent abdominal pain at least one day per week in the last three months, with symptom onset at least six months prior to diagnosis, associated with defecation or a change in the frequency or form (appearance) of stool. More than 25% of stool episodes be classified as Bristol Stool Form Scale (BSFS) type 6 or 7, and fewer than 25% as type 1 or 2. In addition, patients were required to exhibit moderate to severe symptoms, defined as an Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) score greater than 175 (on a 500-point scale). Dietary preferences of all participants included non vegetarian options and participants maintain stable dietary habits for at least one month prior to randomization. Moreover, patients aged over 50 were required to provide documentation of a normal colonoscopy performed within the preceding three years.
Exclusion Criteria:
The exclusion criteria included a completion rate of daily diaries of less than 50% during the screening period, a history of organic gastrointestinal disease, such as inflammatory bowel disease, a history of surgical resection of the GI tract or cholecystectomy, a recent diagnosis of Helicobacter pylori infection within the past 2 years, a history of gluten or lactose intolerance, a history of malignancy, or a history of neurological or psychiatric conditions. Additionally, individuals with severe systemic diseases, including uncontrolled diabetes mellitus, hyperthyroidism, or severe hepatic, renal, or cardiac insufficiency, were excluded. The use of probiotic or prebiotic supplements, antibiotics (including rifaximin), prokinetic or antidiarrheal agents, tricyclic antidepressants, or immunosuppressive therapies was not permitted within 4 wk prior to screening. Prohibited conditions during the study period included pregnancy, lactation, or being within 12 months postpartum. Lastly, participants with severe needle phobia, metal allergies, implanted cardiac pacemakers, or a known allergic diathesis were excluded. All participants provided their voluntary, written, informed consent prior to their inclusion.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Huijausvertailija: feikki toistuva transkraniaalinen magneettistimulaatioryhmä
Sham-rTMS-ryhmälle kela asetettiin mPFC:n päälle rTMS-toiminto poistettu käytöstä, ja ennalta tallennettuja akustisia artefakteja soitettiin matkimaan rTMS-ryhmän auditiivista kokemusta.
|
For the sham rTMS group, the coil was placed over the mPFC with the rTMS function disabled, and pre-recorded acoustic artifacts were played to mimic the auditory experience of the rTMS group.
Muut nimet:
|
|
Active Comparator: repeated transcranial magnetic stimulation group
The rTMS group was given 1 Hz/s for 20 minutes for 3 weeks.
|
Patients with IBS-D received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 3 weeks.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Composite response rate
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
The primary outcome measure of this study is the composite response rate on Day 14 of treatment; a composite responder is defined as having both a ≥30% reduction in the weekly average of the worst abdominal pain intensity in the past 24 hours compared with baseline and a ≥50% reduction in the weekly number of days with Bristol Stool Form Scale (BSFS) Type 6 or 7 (diarrheal stools) compared with baseline.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS)
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
Changes in the total score of the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) from baseline to Day 21.
The IBS-SSS ranges from 0 to 500 points and covers five domains: severity and frequency of abdominal pain, bloating, satisfaction with bowel habits, and impact on quality of life.
A reduction of ≥95 points is considered a clinically meaningful improvement.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
|
Irritable Bowel Syndrome Quality of Life (IBS-QOL)
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
IBS-QOL is a validated questionnaire assessing quality of life in IBS patients.
Scores range 0-100; higher scores reflect better quality of life.
A ≥14-point increase indicates clinically significant improvement.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
|
The Bristol Stool Form Scale (BSFS) and Frequency of defecation
Aikaikkuna: Assessment time points were: baseline (1 week pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
The Bristol Stool Form Scale (BSFS): it is adopted to assess bowel habits, with scores from 1 to 7 corresponding to stool types ranging from hardest to softest, where higher scores indicate more severe diarrhea.
|
Assessment time points were: baseline (1 week pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
|
Numeric Rating Scale (NRS)
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
Numeric Rating Scale (NRS) is an 11-point pain rating scale (0 = no pain, 10 = worst pain).
A ≥30% decrease in NRS score indicates clinically significant pain relief.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
|
The Visceral Sensitivity Index (VSI）
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8, and 12.
|
The Visceral Sensitivity Index (VSI): the questionnaire is a 15-item scale used to assess visceral sensitivity.
The total score ranges from 0 to 75 points, with higher scores indicating greater visceral sensitivity.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8, and 12.
|
|
Patient Health Questionnaire-9 (PHQ-9)
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8, and 12.
|
The PHQ-9 is a 9-item validated self-rating scale used to screen and assess the severity of depressive symptoms.
Each item is rated on a 4-point Likert scale over the past two weeks.
Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.
It is widely applied in clinical trials and gastroenterology studies to evaluate emotional comorbidity in IBS patients.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8, and 12.
|
|
Generalized Anxiety Disorder-7 (GAD-7)
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8, and 12.
|
The GAD-7 is a 7-item validated self-reported questionnaire for screening and quantifying the severity of generalized anxiety symptoms.
Participants rate symptom frequency over the preceding two weeks on a 4-point scale.
Total scores range from 0 to 21; higher scores represent greater anxiety severity.
It is routinely used to evaluate anxiety burden in functional gastrointestinal disorders.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8, and 12.
|
|
Pittsburgh Sleep Quality Index (PSQI)
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8, and 12.
|
The PSQI is a validated 19-item self-assessment tool evaluating overall sleep quality over the past one month.
It covers seven components: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medication, and daytime dysfunction.
The global PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
It is the gold standard for assessing sleep disturbance in clinical research.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8, and 12.
|
|
Gut microbiota and metabolites
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment.
|
Gut microbiota refers to the complex community of microorganisms colonizing the human intestinal tract.
Their metabolites are bioactive substances produced by microbial fermentation, including short-chain fatty acids, bile acid metabolites, amino acid derivatives and other small-molecule compounds.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment.
|
|
Methane-hydrogen breath test
Aikaikkuna: Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
The methane-hydrogen breath test is a non-invasive respiratory detection method used to evaluate small intestinal bacterial overgrowth (SIBO) and intestinal transit function.
It detects exhaled hydrogen and methane gas produced by intestinal microbial fermentation.
|
Assessment time points were: baseline (pre-treatment), end of the 3-week treatment, and post-treatment weeks 4, 8 and 12.
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 2025-776-01YJ
- BE2023710 (Muu apuraha/rahoitusnumero: Jiangsu Provincial Department of Science and Technology)
- 82470573 (Muu apuraha/rahoitusnumero: National Natural Science Foundation of China)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .